For the quarter ending 2026-03-31, PRLD has $119,642K in assets. $59,459K in debts. $21,756K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 21,756 | 35,256 | 47,532 | 25,752 |
| Marketable securities | 59,798 | 67,958 | 7,425 | 47,464 |
| Prepaid expenses and other current assets | 3,039 | 2,478 | 3,373 | 3,660 |
| Total current assets | 84,593 | 105,692 | 58,330 | 76,876 |
| Restricted cash | 3,235 | 3,235 | 3,235 | 4,044 |
| Property, plant and equipment, gross | - | 12,042 | - | - |
| Less accumulated depreciation | - | 6,929 | - | - |
| Property and equipment, net | 4,722 | 5,113 | 5,531 | 5,956 |
| Other assets | - | - | 110 | 110 |
| Right-of-use asset | 26,778 | 27,165 | 27,549 | 27,932 |
| Prepaid expenses and other non-current assets | 314 | 110 | - | - |
| Total assets | 119,642 | 141,315 | 94,755 | 114,918 |
| Finance lease liability | - | 0 | 0 | 0 |
| Accounts payable | 2,069 | 3,983 | 2,533 | 4,962 |
| Accrued expenses and other current liabilities | 5,938 | 12,533 | 12,930 | 13,235 |
| Deferred revenue | 30,952 | 33,734 | - | - |
| Operating lease liability | 2,761 | 2,744 | 2,727 | 2,711 |
| Total current liabilities | 41,720 | 52,994 | 18,190 | 20,908 |
| Deferred revenue, net of current portion | 0 | 1,798 | - | - |
| Other liabilities | 2,779 | 2,841 | 2,904 | 2,966 |
| Operating lease liability | 14,960 | 15,045 | 15,127 | 15,206 |
| Total liabilities | 59,459 | 72,678 | 36,221 | 39,080 |
| Common stock-Voting Common Stock | 5 | 5 | 4 | 4 |
| Common stock-Nonvoting Common Stock | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 753,664 | 751,684 | 725,131 | 722,713 |
| Accumulated other comprehensive (loss) income | -41 | 8 | 2 | -1 |
| Accumulated deficit | -693,446 | -683,061 | -666,604 | -646,879 |
| Total stockholders equity | 60,183 | 68,637 | 58,534 | 75,838 |
| Total liabilities and stockholders equity | 119,642 | 141,315 | 94,755 | 114,918 |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)